NC 1 cell therapy

Phase 2Biologic

PPuerta de Hierro University Hospital

NC 1 cell therapy is one of 3 biologic programs targeting Syringomyelia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SyringomyeliaActive, not recruiting

SyringomyeliaPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Syringomyelia

#DrugCompanyPhaseTrials

Thalomid

Bristol-Myers Squibb

Phase 2

1 2

Cystadane

RRECORDATI GROUP

Phase 2

1 3

NC 1 cell therapy

PPuerta de Hierro University Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Syringomyelia1 trial

Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia

Completed·PPuerta de Hierro University Hospital·Phase 2·NCT02807142·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NC 1 cell therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NC 1 cell therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NC 1 cell therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Puerta de Hierro University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: PPuerta de Hierro University Hospital

NC 1 cell therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Syringomyelia1 trial

References

Drug Info

Quick Facts

Related News